Cancer Chemotherapy and Pharmacology

, Volume 67, Issue 6, pp 1429–1434 | Cite as

A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer

  • Masashi Kanai
  • Kenichi Yoshimura
  • Takehiko Tsumura
  • Masanori Asada
  • Chihiro Suzuki
  • Miyuki Niimi
  • Shigemi Matsumoto
  • Takafumi Nishimura
  • Takashi Nitta
  • Kentaro Yasuchika
  • Kojiro Taura
  • Yukiko Mori
  • Akihiko Hamada
  • Naoya Inoue
  • Shinsuke Tada
  • Kazuhiro Yanagihara
  • Shujiro Yazumi
  • Yukio Osaki
  • Tsutomu Chiba
  • Iwao Ikai
  • Masanori Fukushima
  • Shinji Uemoto
  • Etsuro Hatano
Original Article

Abstract

Purpose

We aimed to evaluate the efficacy and safety of gemcitabine/S-1 combination chemotherapy for the treatment of patients with advanced biliary tract cancer.

Methods

Patients with histologically or cytologically confirmed unresectable or recurrent biliary tract cancer were eligible for inclusion. The primary endpoint was overall survival. Gemcitabine was administered intravenously at a dose of 1,000 mg/m2 over 30 min on days 1 and 8, and oral S-1 was administered daily at a dose of 60 mg/m2 on days 1–14. This schedule was repeated every 3 weeks until disease progression or patient refusal.

Results

Twenty-five patients were enrolled between October 2007 and January 2009. Eleven patients (44%) had extrahepatic bile duct cancer, 5 (20%) had intrahepatic bile duct cancer, 8 had gallbladder cancer (32%), and 1 (4%) had ampulla of Vater cancer. The median overall survival time was 12.7 months (95% CI, 8.4–23.5 months), and the 1-year survival rate was 52.0% (95% CI, 31.2–69.2%). Of the 23 patients with evaluable target regions, seven patients experienced a partial response, and an overall response rate was 30.4%. The following grade 3–4 hematological toxicities occurred: neutropenia (56%), leukopenia (24%), anemia (8%) and thrombocytopenia (4%). In spite of the high incidence of grade 3–4 neutropenia, no patients developed febrile neutropenia in the present study. The major grade 3–4 non-hematological toxicities were fatigue (8%), anorexia (8%) and diarrhea (4%).

Conclusions

Gemcitabine/S-1 combination chemotherapy offered a promising survival benefit with acceptable toxicity in patients with advanced biliary tract cancer.

Keywords

Biliary tract cancer Gemcitabine S-1 Chemotherapy 

Notes

Acknowledgments

This work was supported by the Smoking Research Foundation. We thank Hiroe Tada for her valuable support.

References

  1. 1.
    Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063–1069PubMedCrossRefGoogle Scholar
  2. 2.
    Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, Chung JB, Park MS, Yu JS, Yoon DS (2005) Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 104:2753–2758PubMedCrossRefGoogle Scholar
  3. 3.
    Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96:896–902PubMedCrossRefGoogle Scholar
  4. 4.
    Eng C, Ramanathan RK, Wong MK, Remick SC, Dai L, Wade-Oliver KT, Mani S, Kindler HL (2004) A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol 27:565–569PubMedCrossRefGoogle Scholar
  5. 5.
    Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62:849–855PubMedCrossRefGoogle Scholar
  6. 6.
    Furuse J, Okusaka T, MIyazaki M, Tainai H, Nimura Y (2009) A randomized study of gemcitabine/cisplatin versus single-agent gemcitabine in patients with biliary tract cancer. Proc Am Soc Clin Oncol 27: abstract no: 4579Google Scholar
  7. 7.
    Gores GJ (2003) Cholangiocarcinoma: current concepts and insights. Hepatology 37:961–969PubMedCrossRefGoogle Scholar
  8. 8.
    Jarnagin WR, Ruo L, Little SA, Klimstra D, D’Angelica M, DeMatteo RP, Wagman R, Blumgart LH, Fong Y (2003) Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 98:1689–1700PubMedCrossRefGoogle Scholar
  9. 9.
    Kiba T, Nishimura T, Matsumoto S, Hatano E, Mori A, Yasumi S, Doi R, Ikai I, Kitano T, Nishimura T, Yoshikawa K, Ishiguro H, Yanagihara K, Doi E, Teramukai S, Fukushima M (2006) Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. Oncology 70:358–365PubMedCrossRefGoogle Scholar
  10. 10.
    Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23:2332–2338PubMedCrossRefGoogle Scholar
  11. 11.
    Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D, Caspar CB, Mingrone W, Beretta K, Strasser F, Ruhstaller T, Mora O, Herrmann R (2008) Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 26:3702–3708PubMedCrossRefGoogle Scholar
  12. 12.
    Koizumi W, Akiya T, Sato A, Sakuyama T, Sasaki E, Tomidokoro T, Hamada T, Fujimori M, Kikuchi Y, Shimada K, Mine T, Yamaguchi K, Sasaki T, Kurihara M (2010) Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study. Cancer Chemother Pharmacol 65:1093–1099Google Scholar
  13. 13.
    Leonard GD, O’Reilly EM (2005) Biliary tract cancers: current concepts and controversies. Expert Opin Pharmacother 6:211–223PubMedCrossRefGoogle Scholar
  14. 14.
    Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E (2009) A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 63:313–319PubMedCrossRefGoogle Scholar
  15. 15.
    Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H (2006) Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94:1575–1579PubMedGoogle Scholar
  16. 16.
    Oh DY, Cha Y, Choi IS, Yoon SY, Choi IK, Kim JH, Oh SC, Kim CD, Kim JS, Bang YJ, Kim YH (2010) A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Cancer Chemother Pharmacol 65:527–536Google Scholar
  17. 17.
    Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, Saito H, Tsuyuguchi T (2006) Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57:647–653PubMedCrossRefGoogle Scholar
  18. 18.
    Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer W (2001) Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12:183–186PubMedCrossRefGoogle Scholar
  19. 19.
    Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820PubMedCrossRefGoogle Scholar
  20. 20.
    Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Togawa O, Toda N, Yasuda I, Hasebe O, Maetani I, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M (2010) Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 65:1101–1107PubMedCrossRefGoogle Scholar
  21. 21.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  22. 22.
    Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181PubMedCrossRefGoogle Scholar
  23. 23.
    Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D, Tsipras H, Margaris H, Papastratis G, Tzima E, Papadoniou N, Karatzas G, Papalambros E (2004) Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 22:193–198PubMedCrossRefGoogle Scholar
  24. 24.
    Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C (2004) Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91:1769–1774PubMedCrossRefGoogle Scholar
  25. 25.
    Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, Gollins S, Lofts F, Evans L, Meyer T, Anthoney A, Iveson T, Highley M, Osborne R, Bridgewater J (2009) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study—The UK ABC-01 Study. Br J Cancer 101:621–627PubMedCrossRefGoogle Scholar
  26. 26.
    Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281PubMedCrossRefGoogle Scholar
  27. 27.
    von Delius S, Lersch C, Schulte-Frohlinde E, Mayr M, Schmid RM, Eckel F (2005) Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 5:61CrossRefGoogle Scholar
  28. 28.
    Yamauchi J, Kanai M, Matsumoto S, Nishimura T, Yazumi S, Kami K, Kawaguchi Y, Yasuda H, Kitano T, Misawa A, Ishiguro H, Yoshikawa K, Yanagihara K, Fukushima M, Doi R, Chiba T (2008) Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer. Pancreas 36:327–328PubMedCrossRefGoogle Scholar
  29. 29.
    Yanagihara K, Yoshimura K, Niimi M, Yasuda H, Sasaki T, Nishimura T, Ishiguro H, Matsumoto S, Kitano T, Kanai M, Misawa A, Tada H, Teramukai S, Mio T, Fukushima M (2010) Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer. Cancer Chemother Pharmacol 66:913–918Google Scholar
  30. 30.
    Yoshizawa J, Takizawa A, Takeuchi O, Hiraku O, Sasaki K, Morimoto Y, Atsuda K, Inoue G, Suzuki Y, Asanuma F, Yamada Y (2009) Experimental study of combination therapy with S-1 against pancreatic cancer. Cancer Chemother Pharmacol 64:1211–1219PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Masashi Kanai
    • 1
  • Kenichi Yoshimura
    • 2
  • Takehiko Tsumura
    • 3
  • Masanori Asada
    • 4
  • Chihiro Suzuki
    • 2
  • Miyuki Niimi
    • 2
  • Shigemi Matsumoto
    • 1
  • Takafumi Nishimura
    • 1
  • Takashi Nitta
    • 5
  • Kentaro Yasuchika
    • 5
  • Kojiro Taura
    • 5
  • Yukiko Mori
    • 1
  • Akihiko Hamada
    • 6
  • Naoya Inoue
    • 7
  • Shinsuke Tada
    • 8
  • Kazuhiro Yanagihara
    • 1
  • Shujiro Yazumi
    • 4
  • Yukio Osaki
    • 3
  • Tsutomu Chiba
    • 1
    • 8
  • Iwao Ikai
    • 5
  • Masanori Fukushima
    • 2
  • Shinji Uemoto
    • 5
  • Etsuro Hatano
    • 5
  1. 1.Outpatient Oncology UnitKyoto University HospitalKyotoJapan
  2. 2.Translational Research Center, Kyoto University HospitalKyotoJapan
  3. 3.Osaka Red Cross HospitalOsakaJapan
  4. 4.Kitano HospitalOsakaJapan
  5. 5.Department of Surgery, Graduate School of MedicineKyoto University HospitalKyotoJapan
  6. 6.Kyoto Katsura HospitalKyotoJapan
  7. 7.Kansai Denryoku HospitalOsakaJapan
  8. 8.Department of Gastroenterology and HepatologyKyoto University HospitalKyotoJapan

Personalised recommendations